Amy Degueme, MD
Endocrinology, Diabetes & Metabolism · Mequon, WINPI 1548436371
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $121,721 of the $142,703 with a category attached, or 85.3%. Novo Nordisk accounts for 96.1% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $54,397, 2.9 times the $18,529 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 401 payments — averaging $355.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$137K
- Lilly USA, LLC$870
- Amgen$615
- IBSA Pharma Inc.$545
- AstraZeneca$499
- Bayer$499
- plus $3K from 18 others
What the payments were for
- Consulting fees$3,8183%
- Speaking & faculty fees$121,72185%
- Travel & lodging$6,1824%
- Food & beverage$10,9048%
- Education$190%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 218 | $137,112 |
| Lilly USA, LLC | 37 | $870 |
| Amgen(2 entities) | 15 | $615 |
| IBSA Pharma Inc. | 20 | $545 |
| AstraZeneca | 12 | $499 |
| Bayer | 14 | $499 |
| Sanofi-aventis U.S. LLC | 13 | $498 |
| Johnson & Johnson | 4 | $489 |
| Xeris Pharmaceuticals, Inc. | 16 | $297 |
| Ascendis Pharma Endocrinology Inc | 6 | $219 |
| Halozyme Inc | 6 | $212 |
| Medtronic(2 entities) | 8 | $182 |
| Antares Pharma, Inc. | 6 | $107 |
| Insulet Corporation | 5 | $97 |
| Corcept Therapeutics | 5 | $93 |
| Abbott | 4 | $86 |
| Mannkind Corporation | 1 | $59 |
| Ascensia Diabetes Care US Inc. | 2 | $47 |
| Astellas Pharma US Inc | 2 | $45 |
| Tandem Diabetes Care, Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$142,703 in reported general payments places this provider in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 298 | $562,748 |
| KorlymMifepristone | 13 | $511,466 |
| MounjaroTirzepatide | 189 | $264,593 |
| TrulicityDulaglutide | 39 | $80,661 |
| JardianceEmpagliflozin | 50 | $69,801 |
| Tresiba Flextouch U-200Insulin Degludec | 63 | $49,536 |
| JanuviaSitagliptin Phosphate | 26 | $38,584 |
| FarxigaDapagliflozin Propanediol | 28 | $36,145 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $25,402 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 19 | $24,715 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 27 | $22,587 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $16,044 |
| Humalog Kwikpen U-100Insulin Lispro | 42 | $14,996 |
| Novolog FlexpenInsulin Aspart | 40 | $14,531 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $13,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog | $137,112 | $595,377332 claims |
| Corcept TherapeuticsKorlym | $93 | $511,46613 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $870 | $354,117254 claims |
| AstraZenecaFarxiga | $499 | $36,14528 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $498 | $11,47114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Mequon
- Aron AdkinsEau Claire$349K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
- Vinay PatelNeenah$64K
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
- Adriana IoachimescuMilwaukee$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.